Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Neuronal Ceroid Lipofuscinosis CLN5: early-phase trial registry

1 of 2 indexed Neuronal Ceroid Lipofuscinosis CLN5 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Neuronal Ceroid Lipofuscinosis CLN5: 2 US clinical trials tracked, 1 recruiting.

Neuronal Ceroid Lipofuscinosis CLN5 is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Neurogene, running 1 of these trials.

Enrollment posture brief

Registry condition neuronal-ceroid-lipofuscinosis-cln5

OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Neuronal Ceroid Lipofusc (th…50%
Open-enrollment share among volume-matched conditions near Neuronal Ceroid Lipofuscinosis CLN5

Neuronal Ceroid Lipofuscinosis CLN5 lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Neuronal Ceroid Lipofuscinosis CLN5 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Neuronal Ceroid Lipofuscinosis CLN5 is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Neuronal Ceroid Lipofuscinosis CLN5 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

NGN-101 Genetic
1 trials

US sites by state

Facility locations filed on Neuronal Ceroid Lipofuscinosis CLN5 trials. A trial with sites in several states counts in each.

New York 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Neuronal Ceroid Lipofuscinosis CLN5 page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Neuronal Ceroid Lipofuscinosis CLN5 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Neurogene sponsors the most Neuronal Ceroid Lipofuscinosis CLN5 trials on record, review their full trial history before evaluating a specific study. See Neurogene's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuronal Ceroid Lipofuscinosis CLN5 condition card totals 2 registered trials; most-linked intervention NGN-101; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.